JPRN-jRCTs031210355进行中（未招募）2 期
Phase II study of atezolizumab plus bevacizumab combination therapy for the patients with unresectable hepatocellular carcinoma and Child-Pugh B - CHALLENGE trial
Ikeda Masafumi0 个研究点目标入组 30 人开始时间: 2021年10月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Clinically diagnosed as hepatocellular carcinoma
- •2) Unsuitable for local therapy
- •3) Child-Pugh score of 7 or 8
- •4) 20 years old or older
- •5) ECOG Performance status of 0 or 1
- •6) Presence of target lesion
- •7) No prior systemic therapy
- •8) Preserved major organ function
- •9) Written informed consent
排除标准
- •1) Active double cancer
- •2) Active infection requiring systemic treatments
- •3) Fever of 38 degrees celsius or higher
- •4) Pregnant or lactating women, or women of childbearing potential or her partner
- •5) Mental disorder
- •6) Autoimmune disease
- •7) Taking antiplatelet or anticoagulant medication
- •8) A history of hepatic encephalopathy within 3 months
- •9) Refractory ascites
- •10) Bleeding risk of esophageal and gastric varices
- •11) Metastases to central nervous system
- •12) Severe complication
- •13) Patients who investigator regards as inappropriate for candidate
研究者
相似试验
进行中（未招募）
2 期
Atezo+Bev study for pretreated patientshepatocellular carcinomaJPRN-jRCT1041200068Yamashita Tatsuya28
已完成
2 期
A Phase II Study of Atezolizumab with Bevacizumab for Patients with Non-Small Cell Non-Squamous Cell Lung Cancer (At Be Study) (Investigator-Initiated Clinical Trial)non-small-cell lung cancerJPRN-jRCT2080223980Takashi Seto (Coordinating Investigator)38
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEfficacy of atezolizumab in combination with non-platinum based chemotherapy and bevacizumab versus the combination of a non-platinum based chemotherapy and bevacizumab in recurrent ovarian cancerMedDRA version: 27.0Level: PTClassification code 10016182Term: Fallopian tube cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 27.0Level: PTClassification code 10057529Term: Ovarian cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-000202-37-LTAGO Research GmbH550
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-NOAGO Research GmbH664
进行中（未招募）
1 期
Evaluation of treatment combination Atezolizumab/Bevacizumab +/- Chemotherapy in patients with recurrent ovarian cancerEUCTR2017-000202-37-DKAGO Research GmbH550